Inventiva S.A. (IVA.PA)
Develops oral drugs to treat liver disease and rare genetic disorders.
3.93+0.00%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+41.1%
The outlook
Inventiva (IVA.PA) is trading near its 52-week lows with analysts overwhelmingly bullish—averaging a Strong Buy rating and setting average price targets roughly 145% above current levels. The stock is mixed relative to its moving averages, reflecting near-term uncertainty despite strong fundamental conviction from coverage.
What’s behind the score
Analyst consensusStrong Buy — 1.2 avg of 5 analysts
Price trendMixed vs its moving averages
52-week range34% of the way from its 52-week low to high
Price targetAvg target +145% vs current price
Analyst price target
~12-month · 5 analysts9.63average target+145.2% vs now
Now 3.93
Low 7.00High 15.37
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$928.3M
52-wk high
6.20
52-wk low
2.76
50-day avg
3.65
200-day avg
4.26
Trailing P/E
—